Market Reaction to the HARMONi‑2 Overall Survival Update
On September 14 2026, shares of Akeso Inc. (09926.HK) rallied nearly 5 % following the release of positive overall‑survival data from the company’s pivotal Phase III HARMONi‑2 trial. The trial evaluated ivonescimab, a next‑generation immuno‑oncology antibody, as first‑line therapy for patients with PD‑L1‑positive non‑small‑cell lung cancer (NSCLC). The updated results, presented at the 2026 World Conference on Lung Cancer (WCLC), showed that ivonescimab significantly outperformed the comparator pembrolizumab, reinforcing the therapeutic’s differentiated positioning and bolstering investor confidence.
Key Findings from HARMONi‑2
| Metric | Ivonescimab | Pembrolizumab | Hazard Ratio (HR) |
|---|---|---|---|
| Median Overall Survival (MOS) | 30.75 months | 22.57 months | 0.73 |
| Overall Survival Events | 234 | — | — |
| PD‑L1 TPS > 50 % Subgroup | — | — | 0.58 |
| Squamous NSCLC Subgroup | — | — | 0.65 |
The 27 % reduction in the risk of death, reflected by the HR of 0.73, is statistically and clinically meaningful. Notably, the benefit was amplified in the high‑expression PD‑L1 subgroup (HR 0.58) and in squamous NSCLC (HR 0.65), underscoring ivonescimab’s potential to address unmet needs within specific patient populations.
Analyst Commentary
Citi’s research note highlighted that the interim data “reinforces ivonescimab’s differentiated advantages” and “positions the drug as a first‑line monotherapy with clear superiority over pembrolizumab.” The broker noted that the 30‑month median overall survival compares favorably with historical benchmarks for first‑line immunotherapy in this disease setting. Moreover, the global readouts remain key, as the company continues to evaluate ivonescimab in other indications and across diverse geographic regions.
Broader Context and Market Implications
- Strategic Positioning: The results validate Akeso’s focus on antibody drug discovery and GMP‑compliant production, aligning with its broader pipeline strategy. The company’s market capitalization of approximately HKD 83 billion positions it as a significant player in the biopharmaceutical sector, with a 52‑week high of HKD 156 and a low of HKD 80.2.
- Investor Sentiment: The nearly 5 % uptick in share price reflects market optimism regarding the drug’s commercial prospects and the potential for accelerated regulatory approvals. The positive data also serve as a catalyst for forthcoming Phase III HARMONi‑7, which will further assess ivonescimab in PD‑L1 high‑expressing NSCLC.
- Competitive Landscape: By demonstrating superiority over pembrolizumab—a leading first‑line therapy—ivonescimab challenges incumbent market leaders and may carve out a substantial share of the rapidly growing NSCLC treatment market.
Outlook
Akeso’s performance in the HARMONi‑2 trial marks a pivotal milestone. The company is now poised to leverage its robust manufacturing capabilities and strategic partnerships to advance ivonescimab through regulatory pathways, potentially reshaping the therapeutic landscape for lung cancer. Investors and stakeholders should monitor the upcoming global Phase III readouts and regulatory milestones, as these will critically influence the drug’s commercial trajectory and the company’s long‑term valuation.
